Monkeypox: An emerging global threat during the COVID-19 pandemic

Lai, Chih‐Cheng; Hsu, Chi‐Kuei; Yen, Muh–Yong; Lee, Ping–Ing; Ko, Wen–Chien; Hsueh, Po‐Ren

doi:10.1016/j.jmii.2022.07.004

Cited by 79 publications

(105 citation statements)

References 42 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported the development of monkeypox in patients with HIV during this outbreak [ 8 , 9 , 10 , 11 , 12 ]. The main reason could be that these HIV cases carry the same risk as men who have sex with men [ 13 ]. Moreover, a recent analysis showed numerous preliminary risk factors, such as being a young man, having sex with other men (MSM), engaging in risky behaviors and activities such as condomless sex, PrEP (pre-exposure prophylaxis) and HIV positivity [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France

et al. 2022

View full text Add to dashboard Cite

People with pre-exposure prophylaxis (PrEP) or living with HIV are a high-risk population for monkeypox virus (MPXV) infection. It is important to achieve high MPXV vaccination coverage rates in this group. This project used self-reporting to assess vaccine hesitancy for the smallpox vaccine and acceptance among men having sex with men with PrEP or living with HIV. In total, 52 (33.6%) participants among the 155 declared their hesitancy to be vaccinated against MPXV. Moreover, 20.7% patients with PrEP declared a hesitant attitude towards the smallpox vaccine compared to 40.2% of the HIV patients, p = 0.013. This difference remained not significant after adjustment for age (p = 0.119) and after adjustment for both age and number of different sexual partners (p = 0.406). Among PrEP people, those who expressed concerns about people getting more vaccines than needed (p = 0.012) were less likely to accept vaccination, whereas an increased number of different sexual partners during the previous month was significantly associated with acceptance of vaccination (p = 0.034). Among HIV people, those who expressed concerns about being infected by MPXV (p < 0.001), those who expressed that the smallpox vaccine should be compulsory for people at risk (p < 0.001) and those with an increased the number of different sexual partners the previous month (p = 0.018) were significantly associated with higher acceptance of MPXV vaccination. Our results suggest that vaccine strategy would be efficient in France with a communication strategy emphasizing the benefits of vaccination and the potential MPXV risk infection for health in PrEP and HIV people. Other preventive actions should be implemented, including reduction in sexual partners.

show abstract

Section: Introductionmentioning

confidence: 99%

Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Also, the first outbreak of human MPXV was reported in that country in 2003. After that it occurred in South Sudan (2005) and Nigeria (2017) [ 19 , 20 ]. Outside of Africa, MPXV outbreak was reported in the Midwest states of the United States of America in 2003 and then observed in United Kingdom, Israel, and Singapore [ 19 , 21 ].…”

Section: Epidemic Scenario Of the Mpxvmentioning

confidence: 99%

“…The incubation period for MPX is typically 7–14 days, but it can last up to three weeks [ 26 ]. The general symptoms of this disease are fever, severe headache, back pain, severe asthenia, myalgia, and lymphadenopathy [ 27 ]. The main difference between MPX and smallpox symptoms is that, unlike smallpox, MPX causes lymphadenopathy [ 28 ].…”

Section: Diagnosismentioning

confidence: 99%

A review on insights and lessons from COVID-19 to the prevent of monkeypox pandemic

Hemati

Farhadkhani²,

Sanami³

et al. 2022

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

“…Monkeypox (MPX) is a viral zoonosis illness caused by the monkeypox virus (MPXV) that has been linked to detrimental effects on both human and animal health, and currently posed a global public health emergency (Banerjee et al 2022;Lai et al 2022;Meo and Jawaid 2022;Mohapatra et al 2022;Saied et al 2022a). Its symptoms are similar to those of smallpox, although it is clinically less severe.…”

Section: Introductionmentioning

confidence: 99%

Monkeypox: An Update on Current Knowledge and Research Advances

Chandran¹,

Dhama

Aslam

et al. 2022

J Exp Bio & Ag Sci

View full text Add to dashboard Cite

The resurgence of the disease in humans that is very similar to smallpox called monkeypox (MPX) disease, caused by the monkeypox virus (MPXV), is the dominant topic of discussion in the scientific and popular press around the world right now. This is taking place as the world celebrates the historic accomplishments made in the fight against the Coronavirus Disease (COVID-19) pandemic MPX is currently thought to pose a risk to the general public's health, particularly in areas with high rates of MPXV infection and close human-wild animal contact. Despite the rarity of MPX outbreaks, they are often caused by human-to-human transmission, especially in households and healthcare settings. Recent decades have seen recurrent outbreaks of the MPX after the smallpox disease was declared eliminated and the consequent cessation of smallpox vaccination programs. MPX has presently spread to several countries throughout the world and posed a global public health emergency, with nearly 45000 confirmed cases in 96 countries and locations, and 12 deaths as of August 24, 2022. Even though this viral illness is thought to be self-limiting, its consequences and feasible pandemic potential seriously jeopardize public health. The main approach to avoiding MPX is to adopt appropriate prevention and control measures, increase awareness of risk factors, and inform the public of the steps they may take to reduce viral exposure. Scientific studies are currently looking at the viability and suitability of the MPX vaccination. This article presents a general introduction to MPXV / MPX along with progress in diagnosis, treatment, vaccination, and prevention and control strategies for tackling this global health emergency.

show abstract

Monkeypox: An emerging global threat during the COVID-19 pandemic

Cited by 79 publications

References 42 publications

Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France

Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France

A review on insights and lessons from COVID-19 to the prevent of monkeypox pandemic

Monkeypox: An Update on Current Knowledge and Research Advances

Contact Info

Product

Resources

About